Andrew Tsai

Jefferies & Co.

Recent Articles about Alto Neuroscience Inc.

How Do Analysts Rate This Biopharma Targeting Psychiatric Disorders 11/20/2025

Alto Neuroscience Inc. (ANRO:NYSE) is developing drug candidates for psychiatric and neurological disorders, utilizing a precision approach rather than a one-size-fits-all method. Read to find out how analysts rate this company.

Co. Speeds Up Development of New Drug for Depression 10/28/2025

Alto Neuroscience Inc. (ANRO:NYSE) plans Phases 2b and 3 trials of its asset, ALTO-207, in treatment-resistant depression, noted a Jefferies report.